Published in Mol Cancer on August 27, 2010
PRAME is a golgi-targeted protein that associates with the Elongin BC complex and is upregulated by interferon-gamma and bacterial PAMPs. PLoS One (2013) 1.46
The structure and regulation of Cullin 2 based E3 ubiquitin ligases and their biological functions. Cell Div (2016) 0.82
Differences in gene expression between mouse and human for dynamically regulated genes in early embryo. PLoS One (2014) 0.81
A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. J Clin Invest (2017) 0.80
Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells. PLoS One (2013) 0.79
Differential expression of PRAMEL1, a cancer/testis antigen, during spermatogenesis in the mouse. PLoS One (2013) 0.77
Preferentially Expressed Antigen of Melanoma (PRAME) and Wilms' Tumor 1 (WT 1) Genes Expression in Childhood Acute Lymphoblastic Leukemia, Prognostic Role and Correlation with Survival. Open Access Maced J Med Sci (2014) 0.75
PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget (2016) 0.75
Opa interacting protein 5 acts as an oncogene in bladder cancer. J Cancer Res Clin Oncol (2017) 0.75
Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc (2009) 32.64
A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature (1997) 11.15
Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem (2007) 4.56
Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A (2006) 3.70
Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. Nature (1994) 3.24
The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A (2005) 3.05
Structural diversity of leucine-rich repeat proteins. J Mol Biol (1998) 3.03
The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell (2005) 2.73
Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity (1997) 2.71
The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A (1996) 2.63
Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood (2006) 2.14
One-megabase sequence analysis of the human immunoglobulin lambda gene locus. Genome Res (1997) 1.77
Analysis of the human E2 ubiquitin conjugating enzyme protein interaction network. Genome Res (2009) 1.68
Cracking the egg: molecular dynamics and evolutionary aspects of the transition from the fully grown oocyte to embryo. Genes Dev (2006) 1.67
Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. J Struct Biol (2006) 1.66
Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res (2008) 1.58
Analysis of a high-throughput yeast two-hybrid system and its use to predict the function of intracellular proteins encoded within the human MHC class III region. Genomics (2004) 1.56
Mapping of four distinct BCR-related loci to chromosome region 22q11: order of BCR loci relative to chronic myelogenous leukemia and acute lymphoblastic leukemia breakpoints. Proc Natl Acad Sci U S A (1987) 1.49
Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun (2008) 1.45
PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol (1998) 1.43
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood (2008) 1.33
Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res (2008) 1.32
Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res (2004) 1.31
The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res (2004) 1.30
Duplication and positive selection among hominin-specific PRAME genes. BMC Genomics (2005) 1.29
Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth. Mol Microbiol (1998) 1.29
Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. J Biol Chem (2000) 1.29
Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J Clin Invest (2009) 1.28
PRAME expression and clinical outcome of breast cancer. Br J Cancer (2008) 1.26
Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat (2007) 1.22
Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene (2003) 1.14
Evolution and functional divergence of NLRP genes in mammalian reproductive systems. BMC Evol Biol (2009) 1.14
mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer (2004) 1.12
Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet (2002) 1.12
Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. Leuk Res (2008) 1.11
The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood (2009) 1.11
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2007) 1.07
The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol (2000) 1.07
Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res (2006) 1.06
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood (2009) 1.06
Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol (2001) 1.04
Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res (2006) 1.04
Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res (2007) 1.04
Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer (2008) 1.03
Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica (2006) 1.02
An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220. J Biol Chem (2003) 0.99
Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Ann Hematol (2008) 0.98
PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet (2002) 0.97
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Haematologica (2008) 0.96
Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer (2007) 0.95
Identification of a new expanding family of genes characterized by atypical LRR domains. Localization of a cluster preferentially expressed in oocyte. FEBS Lett (2003) 0.95
Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res (2005) 0.94
Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck (2006) 0.92
PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. Leuk Res (2006) 0.91
Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. FEBS Lett (2000) 0.91
PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res (2006) 0.90
Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs. Exp Hematol (2008) 0.89
Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med (2006) 0.89
Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leuk Res (2010) 0.88
Opa interacting protein 5 (OIP5) is a novel cancer-testis specific gene in gastric cancer. Ann Surg Oncol (2006) 0.85
Childhood acute myelogenous leukaemia: association between PRAME, apoptosis- and MDR-related gene expression. Eur J Cancer (2006) 0.82
PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia. Cancer Genet Cytogenet (2007) 0.82
The expression of PRAME in chronic lymphoproliferative disorders. Leuk Res (2003) 0.81
Oncogene associated cDNA microarray analysis shows PRAME gene expression is a marker for response to anthracycline containing chemotherapy in patients with diffuse large B-cell lymphoma. J Clin Exp Hematop (2009) 0.81
Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach. Breast Cancer Res Treat (2009) 0.80
Clofarabine induces hypomethylation of DNA and expression of Cancer-Testis antigens. Leuk Res (2009) 0.80
A common fold mediates vertebrate defense and bacterial attack. Science (2007) 3.43
The Apaf-1 internal ribosome entry segment attains the correct structural conformation for function via interactions with PTB and unr. Mol Cell (2003) 2.28
Polypyrimidine-tract-binding protein: a multifunctional RNA-binding protein. Biochem Soc Trans (2008) 2.12
The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target gene. Proc Natl Acad Sci U S A (2008) 2.09
Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene (2003) 1.83
Crystal structure of the dimeric protein core of decorin, the archetypal small leucine-rich repeat proteoglycan. Proc Natl Acad Sci U S A (2004) 1.81
Structure of an integrin-ligand complex deduced from solution x-ray scattering and site-directed mutagenesis. J Biol Chem (2003) 1.81
Conformational changes in the integrin beta A domain provide a mechanism for signal transduction via hybrid domain movement. J Biol Chem (2003) 1.80
p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc Natl Acad Sci U S A (2010) 1.77
Activation of a vinculin-binding site in the talin rod involves rearrangement of a five-helix bundle. EMBO J (2004) 1.73
Polypyrimidine tract binding protein regulates IRES-mediated gene expression during apoptosis. Mol Cell (2006) 1.71
Mapping and consensus sequence identification for multiple vinculin binding sites within the talin rod. J Biol Chem (2005) 1.68
Integrin activation involves a conformational change in the alpha 1 helix of the beta subunit A-domain. J Biol Chem (2002) 1.65
Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res (2009) 1.63
A vinculin binding domain from the talin rod unfolds to form a complex with the vinculin head. Structure (2005) 1.56
Translational reprogramming following UVB irradiation is mediated by DNA-PKcs and allows selective recruitment to the polysomes of mRNAs encoding DNA repair enzymes. Genes Dev (2009) 1.56
Quaternary organization of GPIb-IX complex and insights into Bernard-Soulier syndrome revealed by the structures of GPIbβ and a GPIbβ/GPIX chimera. Blood (2011) 1.54
Identification of a motif that mediates polypyrimidine tract-binding protein-dependent internal ribosome entry. Genes Dev (2005) 1.53
Glycoprotein Ibalpha inhibitor complex structure reveals a combined steric and allosteric mechanism of von Willebrand factor antagonism. Blood (2009) 1.51
Crystal structure of the platelet glycoprotein Ib(alpha) N-terminal domain reveals an unmasking mechanism for receptor activation. J Biol Chem (2002) 1.46
PRAME is a golgi-targeted protein that associates with the Elongin BC complex and is upregulated by interferon-gamma and bacterial PAMPs. PLoS One (2013) 1.46
Identification of internal ribosome entry segment (IRES)-trans-acting factors for the Myc family of IRESs. Mol Cell Biol (2007) 1.44
Structural and dynamic characterization of a vinculin binding site in the talin rod. Biochemistry (2006) 1.40
Bag-1 internal ribosome entry segment activity is promoted by structural changes mediated by poly(rC) binding protein 1 and recruitment of polypyrimidine tract binding protein 1. Mol Cell Biol (2004) 1.38
Structure and function of factor XI. Blood (2010) 1.37
Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol (2006) 1.36
Structural determinants of integrin binding to the talin rod. J Biol Chem (2009) 1.35
Integrin structure: heady advances in ligand binding, but activation still makes the knees wobble. Trends Biochem Sci (2003) 1.30
Integrin connections to the cytoskeleton through talin and vinculin. Biochem Soc Trans (2008) 1.30
Central region of talin has a unique fold that binds vinculin and actin. J Biol Chem (2010) 1.21
Dysregulation of protein synthesis and disease. J Pathol (2010) 1.21
Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. J Biol Chem (2001) 1.20
The activity of the vinculin binding sites in talin is influenced by the stability of the helical bundles that make up the talin rod. J Biol Chem (2006) 1.15
Structural diversity in p160/CREB-binding protein coactivator complexes. J Biol Chem (2006) 1.14
Staphylococcus aureus protein A binding to von Willebrand factor A1 domain is mediated by conserved IgG binding regions. FEBS J (2006) 1.13
L-Myc protein synthesis is initiated by internal ribosome entry. RNA (2004) 1.03
ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acids Res (2006) 1.02
T:G mismatch-specific thymine-DNA glycosylase (TDG) as a coregulator of transcription interacts with SRC1 family members through a novel tyrosine repeat motif. Nucleic Acids Res (2005) 1.01
The importance of vicinal cysteines, C1669 and C1670, for von Willebrand factor A2 domain function. Blood (2010) 1.00
An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220. J Biol Chem (2003) 0.99
A Conserved alpha-helical motif mediates the binding of diverse nuclear proteins to the SRC1 interaction domain of CBP. J Biol Chem (2004) 0.99
MOZ fusion proteins in acute myeloid leukaemia. Biochem Soc Symp (2006) 0.98
Structural basis for native agonist and synthetic inhibitor recognition by the Pseudomonas aeruginosa quorum sensing regulator PqsR (MvfR). PLoS Pathog (2013) 0.95
Factor XI interacts with the leucine-rich repeats of glycoprotein Ibalpha on the activated platelet. J Biol Chem (2004) 0.93
MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function. Mol Cell Biol (2005) 0.92
Structural rearrangement in an RsmA/CsrA ortholog of Pseudomonas aeruginosa creates a dimeric RNA-binding protein, RsmN. Structure (2013) 0.91
The double PHD finger domain of MOZ/MYST3 induces α-helical structure of the histone H3 tail to facilitate acetylation and methylation sampling and modification. Nucleic Acids Res (2013) 0.91
Functional interaction of CREB binding protein (CBP) with nuclear transport proteins and modulation by HDAC inhibitors. Cell Cycle (2006) 0.91
The crystal structure of the platelet activator aggretin reveals a novel (alphabeta)2 dimeric structure. Biochemistry (2008) 0.90
MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators. J Biol Chem (2006) 0.89
Structure of the USP15 N-terminal domains: a β-hairpin mediates close association between the DUSP and UBL domains. Biochemistry (2011) 0.89
Structural insights into the targeting of mRNA GU-rich elements by the three RRMs of CELF1. Nucleic Acids Res (2013) 0.87
Effects of glucocorticoids on STAT4 activation in human T cells are stimulus-dependent. J Leukoc Biol (2006) 0.86
Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells. BMC Cancer (2013) 0.86
Structure of Mycobacterium tuberculosis thioredoxin C. Acta Crystallogr D Biol Crystallogr (2006) 0.85
Interleukin-4-inducing principle from Schistosoma mansoni eggs contains a functional C-terminal nuclear localization signal necessary for nuclear translocation in mammalian cells but not for its uptake. Infect Immun (2011) 0.84
Platelet-type von Willebrand disease: new insights into the molecular pathophysiology of a unique platelet defect. Semin Thromb Hemost (2013) 0.84
eIF4A inhibition allows translational regulation of mRNAs encoding proteins involved in Alzheimer's disease. PLoS One (2010) 0.83
SUMOylation regulates the nuclear mobility of CREB binding protein and its association with nuclear bodies in live cells. Biochem Biophys Res Commun (2009) 0.83
Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action. Int J Neuropsychopharmacol (2008) 0.82
Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors. J Med Chem (2014) 0.82
Structure and catalytic regulatory function of ubiquitin specific protease 11 N-terminal and ubiquitin-like domains. Biochemistry (2014) 0.81
Sequence determinants for the tandem recognition of UGU and CUG rich RNA elements by the two N--terminal RRMs of CELF1. Nucleic Acids Res (2011) 0.81
Ring structure of the Escherichia coli DNA-binding protein RdgC associated with recombination and replication fork repair. J Biol Chem (2007) 0.81
End-stapled homo and hetero collagen triple helices: a click chemistry approach. Chem Commun (Camb) (2010) 0.81
Analysis of pre-mRNA and pre-rRNA processing factor Snu13p structure and mutants. Biochem Biophys Res Commun (2007) 0.80
Structure of Mycobacterium tuberculosis thioredoxin in complex with quinol inhibitor PMX464. Protein Sci (2011) 0.79
A signature motif mediating selective interactions of BCL11A with the NR2E/F subfamily of orphan nuclear receptors. Nucleic Acids Res (2013) 0.79
The structure of integrin α1I domain in complex with a collagen-mimetic peptide. J Biol Chem (2013) 0.79
Structure of human thioredoxin exhibits a large conformational change. Protein Sci (2010) 0.78
Assignments of human integrin α1I domain in the apo and Mg²⁺ bound states. Biomol NMR Assign (2013) 0.77
SF2/ASF TORCs up translation. Mol Cell (2008) 0.77
Convergent recognition of a triple helical hydrophobic motif in collagen. Structure (2010) 0.76
Evidence against a protein in plasma that is a product of a factor XI mRNA splice variant missing exons 6 and 7. Blood (2010) 0.75
Correction: PRAME Is a Golgi-Targeted Protein That Associates with the Elongin BC Complex and Is Upregulated by Interferon-Gamma and Bacterial PAMPs. PLoS One (2015) 0.75
A novel D235Y mutation in the GP1BA gene enhances platelet interaction with von Willebrand factor in an Iranian family with platelet-type von Willebrand disease. Thromb Haemost (2012) 0.75
Corrigendum: Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome. Clin Endocrinol (Oxf) (2017) 0.75
Co-ordinated regulation of translation following DNA damage. Cell Cycle (2009) 0.75